...
首页> 外文期刊>American Journal of Cancer Research >Long non-coding RNA CCAT2 promotes gastric cancer proliferation and invasion by regulating the E-cadherin and LATS2
【24h】

Long non-coding RNA CCAT2 promotes gastric cancer proliferation and invasion by regulating the E-cadherin and LATS2

机译:长非编码RNA CCAT2通过调节E-钙粘蛋白和LATS2促进胃癌的增殖和侵袭

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Dysregulation of long non-coding RNAs (lncRNAs) play important roles in tumor development and progression. The long non-coding RNA CCAT2 has been identified to be up-regulated in gastric cancer (GC). However, the detailed molecular mechanism of CCAT2 involved in GC progression is still unknown. The aim of this study was to explore the expression and role of CCAT2 in GC progression. In the study, the expression levels of CCAT2 were significantly up-regulated in 108 cases GC tissues compared with adjacent non-tumor tissues by qRT-PCR analysis. Higher CCAT2 expression was correlated with tumor size, lymph node metastasis and Tumor Node Metastasis (TNM) stage in GC patients. Multivariate analysis showed that lymph node metastasis, TNM stage and the expression of CCAT2 were independent prognostic indicator for disease-free survival (DFS) and the over survival time (OS) for GC patients. Further function analysis demonstrated that knockdown of CCAT2 inhibited the cell migration and invasion, whereas, the overexpression of CCAT2 showed the opposite results in GC cells. Our results also demonstrated that CCAT2 promoted the GC cells epithelial-mesenchymal transition (EMT) by downregulated the E-cadherin expression and upregulated the ZEB2, Vimentin and N-cadherin expression. Moreover, RNA immunoprecipitation (RIP) and Chromatin immunoprecipitation (ChIP) revealed that CCAT2 interacted with EZH2 and regulated the E-cadherin and LATS2 expression. Thus, our results demonstrated that CCAT2 functioned as an oncogene in GC and was involved in gastric cancer progression. Targeting CCAT2 might be a potential therapeutic target for GC.
机译:长的非编码RNA(lncRNA)的失调在肿瘤的发生和发展中起重要作用。长期的非编码RNA CCAT2已被确定在胃癌(GC)中被上调。但是,尚不清楚CCAT2参与GC进展的详细分子机制。这项研究的目的是探讨CCAT2在GC进展中的表达及其作用。通过qRT-PCR分析,与相邻的非肿瘤组织相比,在108例GC组织中,CCAT2的表达水平显着上调。 CCAT2的较高表达与GC患者的肿瘤大小,淋巴结转移和肿瘤转移(TNM)阶段有关。多变量分析表明,淋巴结转移,TNM分期和CCAT2的表达是GC患者无病生存期(DFS)和生存期(OS)的独立预后指标。进一步的功能分析表明,敲低CCAT2抑制了细胞的迁移和侵袭,而CCAT2的过表达在GC细胞中显示出相反的结果。我们的结果还表明,CCAT2通过下调E-钙粘蛋白表达并上调ZEB2,Vimentin和N-钙粘蛋白表达来促进GC细胞上皮-间质转化(EMT)。此外,RNA免疫沉淀(RIP)和染色质免疫沉淀(ChIP)显示CCAT2与EZH2相互作用并调节E-钙粘蛋白和LATS2的表达。因此,我们的结果证明CCAT2在GC中起癌基因的作用,并参与胃癌的进展。靶向CCAT2可能是GC的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号